Close
Back to ACOR Stock Lookup
Pages: 1 2 3 4 5 6 »» Last Page

Acorda Therapeutics (ACOR) – Company Press Releases

Apr 15, 2024 05:03 PM Acorda Therapeutics Announces Delisting from Nasdaq
Apr 3, 2024 05:30 PM Acorda Therapeutics Announces Nasdaq Delisting Notification
Apr 1, 2024 06:35 PM Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Apr 1, 2024 04:01 PM Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
Mar 25, 2024 04:01 PM Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Jan 11, 2024 08:01 AM Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Nov 13, 2023 04:01 PM Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Nov 6, 2023 04:01 PM Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
Nov 6, 2023 08:00 AM Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Aug 8, 2023 04:01 PM Acorda Therapeutics Reports Second Quarter 2023 Financial Results
Aug 2, 2023 08:00 AM Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
Aug 1, 2023 08:00 AM Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
Jun 28, 2023 05:08 PM Tom Burns Elected to the Acorda Therapeutics Board of Directors
Jun 26, 2023 08:00 AM Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
Jun 2, 2023 04:01 PM Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
May 31, 2023 04:01 PM Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
May 30, 2023 08:00 AM Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
May 11, 2023 04:01 PM Acorda Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023 07:00 AM Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 8, 2023 07:00 AM Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
May 4, 2023 09:41 AM Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
Apr 24, 2023 08:00 AM Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
Apr 3, 2023 08:00 AM Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
Mar 27, 2023 08:00 AM Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
Mar 9, 2023 07:00 AM Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 7, 2023 07:00 AM ESTEVE Launches INBRIJA® in Spain
Mar 6, 2023 03:43 PM Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
Feb 14, 2023 04:46 PM Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
Jan 31, 2023 04:01 PM Acorda Therapeutics to Present at Sequire Biotechnology Conference
Jan 5, 2023 04:20 PM Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
Dec 22, 2022 08:00 AM Acorda Therapeutics Announces Revised Long-Term Financial Guidance
Dec 20, 2022 05:30 PM Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
Dec 5, 2022 07:01 AM Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
Nov 11, 2022 09:52 AM Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
Nov 4, 2022 09:25 AM Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Nov 1, 2022 04:01 PM Acorda Therapeutics Reports Third Quarter 2022 Financial Results
Oct 27, 2022 07:00 AM Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
Oct 25, 2022 04:01 PM Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
Oct 21, 2022 07:00 AM Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
Oct 19, 2022 07:00 AM ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
Oct 18, 2022 07:00 AM Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
Oct 16, 2022 04:48 PM Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
Oct 10, 2022 06:30 AM Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
Sep 8, 2022 04:01 PM Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 29, 2022 07:00 AM Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
Aug 19, 2022 08:00 AM Acorda Therapeutics Announces Resignation of Chief Operating Officer
Aug 4, 2022 04:01 PM Acorda Therapeutics Reports Second Quarter 2022 Financial Results
Jul 28, 2022 04:01 PM Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
Jun 16, 2022 07:01 AM Esteve Launches INBRIJA® in Germany
May 11, 2022 04:01 PM Acorda Therapeutics Reports First Quarter 2022 Financial Results
Pages: 1 2 3 4 5 6 »» Last Page

Back to ACOR Stock Lookup